← Oncology Approval Tracker

FDA DECISION ·

Pluvicto

lutetium Lu 177 vipivotide tetraxetan · Advanced Accelerator Applications / Novartis

FDA approvalNew therapyProstate cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with PSMA-positive metastatic castration-resistant prostate cancer previously treated with an androgen receptor pathway inhibitor and taxane chemotherapy.

LAMPGEN ANALYSIS

Why it matters

The original approval links PSMA-directed radioligand therapy to a positive imaging result and two prior treatment classes.

What research teams should watch

Coordinate PSMA imaging, nuclear medicine referral, treatment delivery, and radiation-safety counseling.

PRIMARY RECORDS

Sources